PET and SPECT imaging of melanoma: the state of the art.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 29085965.
- Also identified by DOI 10.1007/s00259-017-3839-5 and PMC identifier 5700861.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Melanoma represents the most aggressive form of skin cancer, and its incidence continues to rise worldwide. <sup>18</sup>F-FDG PET imaging has transformed diagnostic nuclear medicine and has become an essential component in the management of melanoma, but still has its drawbacks. With the rapid growth in the field of nuclear medicine and molecular imaging, a variety of promising probes that enable early diagnosis and detection of melanoma have been developed. The substantial preclinical success of melanin- and peptide-based probes has recently resulted in the translation of several radiotracers to clinical settings for noninvasive imaging and treatment of melanoma in humans. In this review, we focus on the latest developments in radiolabeled molecular imaging probes for melanoma in preclinical and clinical settings, and discuss the challenges and opportunities for future development.
Medical subject headings
- Melanoma
- Radiopharmaceuticals
- Tomography, Emission-Computed, Single-Photon